Livermore

VR Adviser, LLC

SEC CIK
0001615982

Holdings, Q2 2026

Positions as of Jun 30, 2026, filed Aug 14, 2026.SEC

Positions
33
0 vs. Q1 2026
Total value
$3.3B
+$618.93M (+23.1%) vs. Q1 2026

Compare with Q1 2026: new, added, reduced and sold out

Positions

Long positions only. Changes compare share counts with Q1 2026.

VR Adviser, LLC holdings in Q2 2026
SecurityClassSharesValue% of portfolioChange in sharesActionHistory
APOGEE THERAPEUTICS INC03770N101COM8,493,321$1.13B34.18%00.0%Unchanged–
ORKAORUKA THERAPEUTICS INCCOM4,148,428$394.81M11.97%00.0%UnchangedView
ERASERASCA INCCOM17,891,812$327.78M9.94%+1,509,000+9.2%AddedView
SYRESPYRE THERAPEUTICS INCCOM NEW2,985,448$265.05M8.04%−700,000−19.0%ReducedView
DNTHDIANTHUS THERAPEUTICS INCCOM1,180,000$115.03M3.49%00.0%UnchangedView
OCULOCULAR THERAPEUTIX INCCOM10,346,926$101.61M3.08%00.0%UnchangedView
DMRADAMORA THERAPEUTICS INCCOM NEW3,603,595$93.73M2.84%00.0%UnchangedView
SVRASAVARA INCCOM14,745,943$90.84M2.75%+1,005,568+7.3%AddedView
JBIOJADE BIOSCIENCES INCCOM NEW3,220,364$71.56M2.17%00.0%UnchangedView
COGTCOGENT BIOSCIENCES INCCOM1,642,166$63.55M1.93%−357,834−17.9%ReducedView
VRDNVIRIDIAN THERAPEUTICS INCCOM3,257,917$59.85M1.81%−624,792−16.1%ReducedView
VORVOR BIOPHARMA INCCOM NEW3,041,719$56M1.70%00.0%UnchangedView
DYNDYNE THERAPEUTICS INCCOM2,173,913$48.28M1.46%00.0%UnchangedView
MAZEMAZE THERAPEUTICS INCCOM1,602,034$47.8M1.45%00.0%UnchangedView
RLMDRELMADA THERAPEUTICS INCCOM6,844,305$47.36M1.44%+2,000,925+41.3%AddedView
ORICORIC PHARMACEUTICALS INCCOM4,319,765$46.78M1.42%00.0%UnchangedView
CBIOCRESCENT BIOPHARMA INC.COM2,133,576$38.4M1.16%00.0%UnchangedView
ZURAZURA BIO LTDCLASS A ORD SHS6,434,990$37.97M1.15%00.0%UnchangedView
ANLADLAI NORTYE LTDADS3,212,731$36.95M1.12%00.0%UnchangedView
ELVNENLIVEN THERAPEUTICS INCCOM526,331$26.71M0.81%−1,200,000−69.5%ReducedView
HELPCYBIN INCCOM NEW3,851,654$25.46M0.77%00.0%UnchangedView
CGEMCULLINAN THERAPEUTICS INCCOM1,379,965$25.13M0.76%00.0%UnchangedView
IPSCCENTURY THERAPEUTICS INCCOM8,695,652$21.3M0.65%00.0%UnchangedView
ARTVARTIVA BIOTHERAPEUTICS INCCOM2,043,596$19.82M0.60%+434,027+27.0%AddedView
CTMXCYTOMX THERAPEUTICS INC.COM4,982,124$18.68M0.57%−5,000,000−50.1%ReducedView
ACHVACHIEVE LIFE SCIENCE INCCOM2,751,032$17.96M0.54%+2,751,032NewView
PBLSPARABILIS MEDICINES INC COMStock625,000$17.11M0.52%+625,000NewView
SRZNSURROZEN INCCOM NEW632,931$16.42M0.50%00.0%UnchangedView
KRROKORRO BIO INCCOM1,009,500$13.31M0.40%00.0%UnchangedView
ANROALTO NEUROSCIENCE INCCOM SHS500,000$13.2M0.40%00.0%UnchangedView
XFORX4 PHARMACEUTICALS INCCOM NEW1,934,253$9.03M0.27%+1,603,728+485.2%AddedView
RACCRESEARCH ALLIANCE CORP IIIORD SHS CL A300,000$3.21M0.10%+300,000NewView
INMINMED PHARMACEUTICALS INCCommon Stock32,685$50.66K0.00%+32,685NewView

Sold out since Q1 2026 (4)

Positions held at the end of Q1 2026 that are no longer in this filing.

VR Adviser, LLC positions sold out since Q1 2026
SecurityClassShares, Q1 2026Value, Q1 2026% of portfolio, Q1 2026
KALVISTA PHARMACEUTICALS INC483497103COM6,474,485$130.33M4.86%
ENGNENGENE HOLDINGS INCCOM4,771,414$32.49M1.21%
TENXTENAX THERAPEUTICS INCCOM NEW1,675,262$26.79M1.00%
SEPNSEPTERNA INCCOM506,056$12.16M0.45%

13F filings by quarter

VR Adviser, LLC 13F filings by quarter
QuarterFiledPositionsTotal valueChangesFiling
Q2 2026Aug 14, 202633$3.3Bvs. Q1 2026SEC
Q1 2026May 15, 202633$2.68Bvs. Q4 2025SEC
Q4 2025Feb 17, 202627$2.02Bvs. Q3 2025SEC
Q3 2025Nov 14, 202533$1.78Bvs. Q2 2025SEC
Q2 2025Aug 14, 202531$1.33Bvs. Q1 2025SEC
Q1 2025May 15, 202537$1.18Bvs. Q4 2024SEC
Q4 2024Feb 14, 202537$1.46Bvs. Q3 2024SEC
Q3 2024Nov 14, 202438$1.91Bvs. Q2 2024SEC
Q2 2024Aug 14, 202435$1.57Bvs. Q1 2024SEC
Q1 2024May 15, 202438$2.1Bvs. Q4 2023SEC
Q4 2023Feb 14, 202436$1.46Bvs. Q3 2023SEC
Q3 2023Nov 14, 202337$949.95Mvs. Q2 2023SEC
Q2 2023Aug 11, 202330$625.36Mvs. Q1 2023SEC
Q1 2023May 15, 202325$512.17Mvs. Q4 2022SEC
Q4 2022May 15, 2023Amended28$593.6Mvs. Q3 2022SEC
Q3 2022May 15, 2023Amended31$648.09Mvs. Q2 2022SEC
Q2 2022May 15, 2023Amended27$507.78Mvs. Q1 2022SEC
Q1 2022May 16, 202227$617.24Mvs. Q4 2021SEC
Q4 2021Feb 14, 202226$731.54Mvs. Q3 2021SEC
Q3 2021Nov 15, 202126$778.55Mvs. Q2 2021SEC
Q2 2021Aug 13, 202129$824.4Mvs. Q1 2021SEC
Q1 2021May 14, 202128$921.76M–SEC